Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biogen (BIIB) PT Lowered to $294 at Baird
July 29, 2024 6:56 AM EDTBaird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $294.00 (from $316.00) while maintaining a Outperform rating.
The analyst comments "Lowering target on negative CHMP opinion. The initial negative opinion jeopardizes Leqembi's launch in the EU, where we had... More
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $342.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for BIIB/Eisais Leqembi, stating that the slowing of cognitive decline in treated patients does not outweigh the safety risks... More
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM EDTPiper Sandler analyst Christopher Raymond lowered the price target on Biogen (NASDAQ: BIIB) to $307.00 (from $313.00) while maintaining a Overweight rating.
The analyst comments "Conclusion: Remain OW on BIIB shares despite news this morning that the EMAs Committee for Medicinal Products for Human... More
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $282.00 (from $303.00) while maintaining a Outperform rating.
The analyst comments "Our analysis suggests a 20% historical success rate for drugs CHMP re-examines; looking at prior examples over the past 10 years, we... More
